1,433,155 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Sio Capital Management LLC

Sio Capital Management LLC bought a new position in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,433,155 shares of the company's stock, valued at approximately $8,484,000. Annexon accounts for about 3.4% of Sio Capital Management LLC's investment portfolio, making the stock its 11th largest holding. Sio Capital Management LLC owned approximately 1.36% of Annexon at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Candriam S.C.A. acquired a new position in shares of Annexon in the second quarter worth about $10,061,000. Vanguard Group Inc. lifted its position in shares of Annexon by 96.4% in the 1st quarter. Vanguard Group Inc. now owns 3,747,655 shares of the company's stock valued at $26,871,000 after acquiring an additional 1,839,329 shares in the last quarter. Marshall Wace LLP boosted its stake in Annexon by 436.6% in the 2nd quarter. Marshall Wace LLP now owns 1,693,665 shares of the company's stock worth $8,299,000 after purchasing an additional 1,378,053 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Annexon by 10,482.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,323,704 shares of the company's stock valued at $9,492,000 after purchasing an additional 1,311,195 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in Annexon by 16.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company's stock valued at $29,346,000 after purchasing an additional 832,617 shares during the period.

Annexon Price Performance

ANNX traded up $0.05 during midday trading on Friday, hitting $5.39. 757,721 shares of the company's stock traded hands, compared to its average volume of 1,807,955. The stock's fifty day simple moving average is $6.65 and its 200-day simple moving average is $5.95. Annexon, Inc. has a one year low of $2.27 and a one year high of $8.40.

Insider Activity

In related news, EVP Ted Yednock sold 5,408 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total value of $40,073.28. Following the transaction, the executive vice president now directly owns 71,365 shares of the company's stock, valued at approximately $528,814.65. This trade represents a 7.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 15,408 shares of company stock worth $103,043. 12.67% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Annexon in a report on Friday, November 15th. Needham & Company LLC restated a "buy" rating and set a $16.00 price target on shares of Annexon in a report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Annexon in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Annexon presently has an average rating of "Buy" and a consensus price target of $15.80.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.